Literature DB >> 22718207

Global changes in the epidemiology of community-acquired pneumonia.

Timothy L Wiemken1, Paula Peyrani, Julio A Ramirez.   

Abstract

Lower respiratory tract infections are the most common infectious cause of death in the world and the third most common cause of death globally (all causes). This article reviews the epidemiology of community-acquired pneumonia from a global perspective. Major areas of epidemiological work include (1) disease surveillance to define the burden of disease and to document outbreaks, (2) identification of risk factors for a disease to optimize prevention strategies, and (3) comparisons of treatment effects to improve clinical outcomes for patients with the disease. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2012        PMID: 22718207     DOI: 10.1055/s-0032-1315633

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  14 in total

1.  Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.

Authors:  Kristina Öbrink-Hansen; Tore Forsingdal Hardlei; Birgitte Brock; Søren Jensen-Fangel; Marianne Kragh Thomsen; Eskild Petersen; Mads Kreilgaard
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

2.  Moxifloxacin dosing in post-bariatric surgery patients.

Authors:  Pieter Colin; Douglas J Eleveld; Michel M R F Struys; Huybrecht T'Jollyn; Luc M Van Bortel; Johannes Ruige; Jan De Waele; Jan Van Bocxlaer; Koen Boussery
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

3.  Graph Theoretical Analysis of Genome-Scale Data: Examination of Gene Activation Occurring in the Setting of Community-Acquired Pneumonia.

Authors:  Octavia M Peck Palmer; Gary Rogers; Sachin Yende; Derek C Angus; Gilles Clermont; Michael A Langston
Journal:  Shock       Date:  2018-07       Impact factor: 3.454

Review 4.  The use of facemasks to prevent respiratory infection: a literature review in the context of the Health Belief Model.

Authors:  Shin Wei Sim; Kirm Seng Peter Moey; Ngiap Chuan Tan
Journal:  Singapore Med J       Date:  2014-03       Impact factor: 1.858

5.  Using Standardized Interpretation of Chest Radiographs to Identify Adults with Bacterial Pneumonia--Guatemala, 2007-2012.

Authors:  Jonathan M Wortham; Jennifer Gray; Jennifer Verani; Carmen Lucia Contreras; Chris Bernart; Fabiola Moscoso; Juan Carlos Moir; Emma Lissette Reyes Marroquin; Rigoberto Castellan; Wences Arvelo; Kim Lindblade; John P McCracken
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  Use of delta neutrophil index for differentiating low-grade community-acquired pneumonia from upper respiratory infection.

Authors:  Hyunjung Kim; Yonggoo Kim; Kwan Hyoung Kim; Chang Dong Yeo; Jin Woo Kim; Hae Kyung Lee
Journal:  Ann Lab Med       Date:  2015-11       Impact factor: 3.464

Review 7.  Lung ultrasound for the diagnosis of pneumonia in adults: a systematic review and meta-analysis.

Authors:  Miguel A Chavez; Navid Shams; Laura E Ellington; Neha Naithani; Robert H Gilman; Mark C Steinhoff; Mathuram Santosham; Robert E Black; Carrie Price; Margaret Gross; William Checkley
Journal:  Respir Res       Date:  2014-04-23

8.  Risk of contracting pneumonia among patients with predialysis chronic kidney disease: a population-based cohort study in Taiwan.

Authors:  Shih-Wei Lai; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Biomedicine (Taipei)       Date:  2017-08-25

Review 9.  Viral-bacterial interactions-therapeutic implications.

Authors:  Jane C Deng
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

10.  Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).

Authors:  Ilija Kuzman; Alexandr Bezlepko; Irena Kondova Topuzovska; László Rókusz; Liudmyla Iudina; Hans-Peter Marschall; Thomas Petri
Journal:  BMC Pulm Med       Date:  2014-06-30       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.